FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
26/09/2022
Voltar para busca
Dado oficial do USPTO
SANSTEMZA VANDEFITEMCEL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
26/09/2022
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10
Data de depósito
03/08/2020
Data de registro
03/05/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
03/05/2022
Última transação
03/05/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
JP
Examinador
CIANCI, RYAN
Unidade examinadora
M70
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a blue wording "SANSTEMZA" below two blue and yellow rainbows and above the yellow wording "VANDEFITEMCEL". The white background is not claimed as a feature of the mark.
Titulares e representantes
Titulares
SanBio Company Limited
Representantes
N. Alexander Nolte Nolte Lackenbach Siegel
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Stem cells for medical and veterinary purposes; pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of traumatic brain injurycerebral infarctioncerebral hemorrhageage-related macular degenerationretinitis pigmentosaParkinson's diseasespinal cord injuryAlzheimer's disease; all the aforementioned being vandefitemcel that are stem cells affecting fibroblasts for use during cell therapy
Classe 10
Apparatus for the regeneration of stem cells for medical purposes; medical apparatus and instruments used for cell culturefor cell culture chambers; medical apparatus and instrumentscell testing apparatus in the nature of medical diagnostic apparatus for testing cancer cellsDNAblood cells and extra cellular contents; medical apparatus and instrumentsintracellular material injector for medical purposes in the nature of injection instrument with needlesneedle-based and needle-free injection systems; medical apparatus and instruments for monitoring vital signsfor use in orthopedic surgery; medical apparatus and instruments for analyzing substances for medical purposesblood and cell analyzers for medical diagnostics; medical apparatus and instrumentstest tubes for cell separation for medical purposes in the nature of blood testing apparatusblood sampling tubes; medical apparatus and instrumentsapparatus for the regeneration of stem cells for medical purposes; gene and genetic testing apparatus in the nature of apparatus for DNA and RNA testing for medical purposes; medical apparatus and instrumentscell injector for medical purposes in the nature of injection instrument with needles; medical apparatus and instrumentsneedle-based and needle-free injection systems; implants consisting of artificial materials; artificial implants in the nature of surgical implants comprised of artificial materials and artificial vascular grafts
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/09/2022
FIMP
FINAL DISPOSITION PROCESSED
02/09/2022
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
02/09/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
15/08/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/08/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
03/05/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
26/03/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/03/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/03/2022
GPNX
NOTIFICATION PROCESSED BY IB
20/02/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
15/02/2022
PUBO
PUBLISHED FOR OPPOSITION
15/02/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
26/01/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
26/01/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26/01/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/01/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/01/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/01/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/01/2022
RFNP
REFUSAL PROCESSED BY IB
15/08/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/07/2021
GNRT
NON-FINAL ACTION E-MAILED
12/07/2021
CNRT
NON-FINAL ACTION WRITTEN
12/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/06/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/06/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/06/2021
RFNT
REFUSAL PROCESSED BY IB
04/01/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
16/12/2020
RFRR
REFUSAL PROCESSED BY MPU
16/12/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/12/2020
CNRT
NON-FINAL ACTION WRITTEN
02/12/2020
DOCK
ASSIGNED TO EXAMINER
24/11/2020
MAFR
APPLICATION FILING RECEIPT MAILED
17/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
13/10/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/10/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SANSTEMZA VANDEFITEMCEL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.